Nursing Pharmacology
Chapter 33-34: Cancer Chemotherapy Drug Practice Questions
Click on the correct answer.
Folic acid antagonist: binds to catalytic site of dihydrofolate reductase-
- altretamine (Hexalen)
- cisplatin (Platinol)
- methotrexate
- fludarabine (Fludara)
Cellular mechanism(s) of resistance to the action of methotrexate:
- reduce drug transport
- increased polyglutamate formation
- increased levels of dihydrofolate reductase
- A & C
Most common mechanism of resistance to both 6-MP (6-mercaptopurine) and 6-TG (6-thioguanine):
- increased levels of dihydrofolate reductase (DHFR)
- increased drug efflux from the cells by increased active transport
- decreased HGPRT activity
- decreased polyglutamate formation
This pyrimidine analog is used systemically to treat adenocarcinomas, topically for skin cancer and works through inhibition of DNA synthesis.
- cytarabine (ARA-C)
- vinblastine (Velban)
- fluorouracil (5-FU)
- cladribine (Leustatin)
Leucovorin "rescue"
- busulfan (Myleran)
- mercaptopurine (Purinethol)
- methotrexate
- daunorubicin (DaunoXome)
Administrate of this drug concurrently with allopurinol can result in excessive toxicity;
- thioguanine
- mercaptopurine (Purinethol)
- cytarabine (ARA-C)
- fludarabine (Fludara)
|
If
you wish to return to the Table of Contents in ENGLISH, press
the RETURN button above. |
|
Otherwise, if the text is NOT displayed in English and
you are ready to leave this page,
Press here
to return to the Table of Contents
 |